The Claim
In HIV-infected adults on antiretroviral therapy, a nadir CD4+ T-cell count of ≤100 cells/µL is independently associated with a greater reduction in Lp-PLA2 levels following rosuvastatin therapy.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
HIV patients who previously had very low CD4+ T-cell counts experience a larger decrease in Lp-PLA2, a marker of vascular inflammation, after taking rosuvastatin compared to those with higher past CD4+ counts.
See the scientific wording
In HIV-infected adults on antiretroviral therapy, a nadir CD4+ T-cell count of ≤100 cells/µL is independently associated with greater reduction in Lp-PLA2 levels following rosuvastatin therapy, suggesting prior severe immunosuppression may predict enhanced vascular anti-inflammatory response.
When a person had very low immune cell counts in the past, their immune cells become more sensitive to statins. The statin blocks a key chemical pathway inside immune cells called macrophages, which stops them from making a protein called Lp-PLA2. Less Lp-PLA2 means fewer inflammatory chemicals are produced in blood vessel walls, leading to less inflammation. This effect is stronger in people who had severe immune damage before.
What the research says
1 studyPeople with HIV who had very low immune cell counts in the past showed a bigger drop in a blood vessel inflammation marker after taking rosuvastatin, suggesting their blood vessels respond better to the drug.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.